Farxiga Cost in Rhode Island 2026: Cash Price, Medicaid, Savings Cards, and Compounding

What Is the Cash Price of Farxiga in Rhode Island in 2026?

The retail cash price for a 30-day supply of Farxiga 10 mg at Rhode Island pharmacies sits at approximately $620 in 2026, matching AstraZeneca's published list price. Without any discount program, that figure is consistent across large chains including CVS, Walgreens, and independent pharmacies throughout Providence, Warwick, and Cranston.

Why the List Price Rarely Reflects What Patients Pay

Most privately insured patients never pay the full $620. Commercial insurance plans typically place Farxiga on Tier 3 of a formulary, bringing out-of-pocket costs to $50 to $100 per month after deductibles. Patients who qualify for the AstraZeneca savings card pay $0 per month (details below). Uninsured patients face the full list price unless they use a coupon aggregator or compounding pharmacy.

How Rhode Island Retail Prices Compare to National Averages

Rhode Island cash prices mirror the national average because AstraZeneca does not implement state-level pricing variation on the brand product. The meaningful price differences in the state come from the payer mix, specifically Medicaid penetration, employer plan formulary tiers, and access to 503A compounders rather than from geography alone.

Does Rhode Island Medicaid Cover Farxiga?

Rhode Island Medicaid (RIte Care and Rhody Health Options) covers dapagliflozin for qualifying diagnoses, but a prior authorization (PA) is required before the pharmacy can dispense the drug at the Medicaid rate.

Prior Authorization Requirements for RI Medicaid

To obtain PA, prescribers typically must document at least one of the following:

• A confirmed diagnosis of type 2 diabetes (T2D) with an HbA1c above a threshold specified in the current RI Medicaid preferred drug list (PDL).
• A confirmed diagnosis of heart failure with reduced ejection fraction (HFrEF) or heart failure with preserved ejection fraction (HFpEF), consistent with the FDA label expansion following the DAPA-HF trial.
• A diagnosis of chronic kidney disease (CKD) stages 2 to 4 with an eGFR of 25 to 75 mL/min/1.73 m², per the FDA's 2021 CKD indication.

The PA process takes one to five business days in most cases. If denied, prescribers can submit a peer-to-peer review or appeal citing published guidelines from the American Diabetes Association (ADA) or the 2022 AHA/ACC Heart Failure Guidelines.

What RI Medicaid Members Actually Pay

Once PA is approved, RI Medicaid members pay a nominal copay, typically $3.65 for generic-tier drugs and somewhat higher for brand-tier drugs. Dapagliflozin's copay tier may shift as generic versions enter the market. Members should confirm the exact copay with their managed care organization (RIte Care MCO) before filling.

Step Therapy Considerations

Some RI Medicaid MCOs require documented failure of at least one preferred SGLT2 inhibitor (or metformin for T2D) before approving Farxiga. Prescribers can bypass step therapy with clinical justification, such as intolerance to metformin or a specific FDA-labeled indication where dapagliflozin is the studied agent.

Is Compounded Dapagliflozin Legal in Rhode Island?

Yes. Licensed 503A compounding pharmacies in Rhode Island may prepare dapagliflozin compounds for individual patients under a valid prescription from a licensed prescriber. FDA 503A regulations allow state-licensed pharmacies to compound drugs not on the FDA's "difficult to compound" or "do not compound" lists, and dapagliflozin does not currently appear on either list.

503A vs. 503B: What Rhode Island Patients Need to Know

A 503A pharmacy compounds drug products for specific patients on a per-prescription basis. A 503B outsourcing facility compounds in bulk without a patient-specific prescription. Rhode Island patients accessing compounded dapagliflozin will almost always work with a 503A pharmacy.

The Rhode Island Board of Pharmacy licenses and inspects 503A facilities operating within the state. Out-of-state 503A pharmacies may also ship to Rhode Island patients, provided those pharmacies hold a valid non-resident pharmacy license issued by the RI Department of Health.

Cost of Compounded Dapagliflozin in Rhode Island

Compounded dapagliflozin through a licensed 503A pharmacy can cost significantly less than brand-name Farxiga. Some telehealth platforms that partner with 503A pharmacies offer compounded dapagliflozin at costs ranging from $0 to $80 per month depending on the platform's subscription model and the pharmacy's pricing structure. This is a meaningful difference compared to the $620 list price for brand Farxiga.

Clinical Cautions with Compounded Dapagliflozin

Compounded products are not FDA-approved and have not undergone the same bioequivalence testing as Farxiga. Prescribers should review the pharmacy's certificate of analysis and confirm the active pharmaceutical ingredient (API) source before prescribing. Patients switching from brand Farxiga to a compounded version should have their metabolic markers, specifically HbA1c, eGFR, and blood pressure, monitored within 60 to 90 days of the switch.

How Does the AstraZeneca Farxiga Savings Card Work in Rhode Island?

AstraZeneca's savings card program for Farxiga allows eligible commercially insured Rhode Island patients to pay $0 per month for a 30-day supply. The program is not available to patients enrolled in any federal or state government insurance program, including Medicare, Medicaid, TRICARE, or VA benefits.

Eligibility Criteria

To use the AstraZeneca savings card in Rhode Island, a patient must:

1. Have a valid prescription for Farxiga from a licensed Rhode Island prescriber.
2. Hold commercial (private) insurance that covers Farxiga (even partially).
3. Be a legal resident of the United States.
4. Not be enrolled in Medicare, RI Medicaid, or any other government-funded plan.

The $0 copay applies up to a program maximum per year, which AstraZeneca sets annually. As of the 2025 to 2026 program year, the cap has been set at $6,500 per calendar year. Patients whose annual Farxiga cost would exceed that figure should contact AstraZeneca's patient support line directly.

How to Activate the Card in Rhode Island

Patients can enroll online at AstraZeneca's manufacturer website or ask their prescriber's office to complete the enrollment during the visit. The card is accepted at most Rhode Island retail pharmacies. Some specialty pharmacy networks may require a separate enrollment step.

AstraZeneca's AZ&Me Patient Assistance Program

Uninsured Rhode Island patients who do not qualify for the savings card may be eligible for the AZ&Me Prescription Savings Program, which can provide Farxiga at no cost for patients meeting income thresholds (generally at or below 600% of the federal poverty level). Enrollment requires prescriber documentation and proof of income.

Which Insurance Plans Cover Farxiga in Rhode Island?

Most major commercial plans operating in Rhode Island include Farxiga on formulary, though tier placement varies.

Major RI Commercial Plans and Formulary Status

• Blue Cross Blue Shield of Rhode Island (BCBSRI): Farxiga is generally listed on Tier 3 (preferred brand) for most plan designs, with copays of $50 to $100 per 30-day fill.
• Tufts Health Plan (Point32Health): Tier 3 placement is common; PA may be required for the HF or CKD indication.
• United Healthcare (RI employer plans): Tier 3; step therapy through a generic SGLT2 may apply.
• Aetna (RI employer plans): Tier 3 to Tier 4 depending on plan design; check the specific plan's Summary of Benefits and Coverage (SBC).

Coverage for the heart failure indication specifically has expanded since the 2019 DAPA-HF trial and the subsequent 2020 FDA approval, and most plans updated their formularies to reflect the new labeled indication within 12 to 18 months of approval.

Medicare Part D and Farxiga

Rhode Island Medicare Part D beneficiaries cannot use the AstraZeneca savings card, but Farxiga appears on multiple Part D formularies in the state. The 2025 IRA-driven $2,000 annual out-of-pocket cap for Part D means high-cost months early in the year should not exceed that total cap for the calendar year. Patients should compare their specific plan's Explanation of Benefits to determine net annual cost.

Clinical Indications That Drive Prescribing in Rhode Island

Understanding which condition Farxiga is prescribed for matters because prior authorization criteria, Medicaid coverage, and insurance tiers can differ by indication.

Type 2 Diabetes

The FDA approved dapagliflozin for T2D in January 2014. The ADA's 2024 Standards of Medical Care recommend SGLT2 inhibitors for patients with T2D who have established cardiovascular disease, heart failure, or CKD, regardless of HbA1c level. The ADA writes: "In patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, an SGLT2 inhibitor with demonstrated cardiovascular benefit is recommended." (ADA Standards of Care, 2024)

Heart Failure

DAPA-HF (N=4,744) demonstrated that dapagliflozin 10 mg once daily reduced the composite of worsening heart failure or cardiovascular death by 26% compared to placebo (hazard ratio 0.74, 95% CI 0.65 to 0.85, P<0.001) in patients with HFrEF, including those without diabetes. [1] The FDA expanded the Farxiga label to include symptomatic HFrEF in May 2020. A further expansion for HFpEF followed in 2022 based on the DELIVER trial.

Chronic Kidney Disease

The DAPA-CKD trial (N=4,304) showed that dapagliflozin reduced the composite primary endpoint of sustained decline in eGFR by 50% or more, end-stage kidney disease, or death from renal or cardiovascular causes by 39% versus placebo (HR 0.61, 95% CI 0.51 to 0.72, P<0.001). [2] The FDA approved dapagliflozin for CKD in April 2021.

Can Rhode Island Patients Get Farxiga Through Telehealth?

Yes. Rhode Island permits telehealth prescribing of Farxiga by licensed prescribers who are authorized to practice in the state. Since Farxiga is not a controlled substance, the DEA's special in-person examination requirements for telemedicine prescribing of controlled substances do not apply.

How Telehealth Prescribing Works for Farxiga in RI

A Rhode Island-licensed physician, nurse practitioner, or physician assistant can evaluate a patient via synchronous video, document an appropriate clinical indication (T2D, HF, or CKD), and transmit the prescription electronically to any RI pharmacy or to a licensed out-of-state compounding pharmacy that ships to Rhode Island. The prescriber must maintain a valid Rhode Island prescribing license and comply with RI Board of Medical Licensure and Discipline telehealth standards.

HealthRX Telehealth Access for Rhode Island Patients

The HealthRX clinical team uses a structured three-step triage protocol for Rhode Island patients requesting dapagliflozin via telehealth:

1. Indication confirmation: The prescriber reviews labs (HbA1c, eGFR, urine albumin-to-creatinine ratio) and confirms at least one FDA-approved indication.
2. Payer pathway selection: Based on the patient's insurance status, the team identifies the lowest-cost dispensing path: brand Farxiga with AstraZeneca savings card, RI Medicaid formulary fill, or licensed 503A compounded dapagliflozin.
3. Monitoring plan: The prescriber establishes a 90-day follow-up to review eGFR, HbA1c, blood pressure, and any signs of genitourinary infection or diabetic ketoacidosis (DKA).

This framework keeps patients on the most affordable, clinically appropriate supply path from the first prescription rather than requiring them to manage payer rules independently.

Safety Profile and Monitoring Requirements for Rhode Island Prescribers

Dapagliflozin is generally well tolerated, but Rhode Island prescribers and patients should be aware of specific adverse effects and monitoring needs.

Key Adverse Effects

• Genitourinary infections: Female patients face a 5 to 8-fold higher rate of vulvovaginal candidiasis compared to placebo in key trials. Male patients face a modest increase in balanitis.
• Euglycemic DKA: Rare but serious. Risk increases perioperatively or during prolonged fasting. Farxiga should be held at least 3 to 4 days before elective surgery.
• Volume depletion: Osmotic diuresis can cause hypotension, particularly in older patients or those on loop diuretics. Starting dose of 5 mg may be preferred in this population.
• Fournier's gangrene: Rare necrotizing fasciitis of the perineum; requires immediate medical evaluation if suspected.

Contraindications

Do not prescribe dapagliflozin to patients with:

• eGFR <25 mL/min/1.73 m² (for the diabetes indication; the CKD indication has different eGFR thresholds per label).
• Type 1 diabetes (not an approved indication for this agent in the United States).
• Active bladder cancer or a history of bladder cancer (listed as a precaution on the FDA label).

Baseline and Follow-Up Labs

Obtain eGFR and urinalysis at baseline. Recheck eGFR at 3 months and at least annually thereafter. For patients with CKD, check urine albumin-to-creatinine ratio every 6 months. HbA1c should be reassessed every 3 months until stable, then every 6 months for T2D patients.

Practical Cost-Reduction Steps for Rhode Island Patients in 2026

Rhode Island patients can take several concrete steps to lower their Farxiga out-of-pocket costs:

1. Apply for the AstraZeneca savings card if you hold commercial insurance. Many patients pay $0 per month after enrollment.
2. Ask your prescriber to submit prior authorization for RI Medicaid if you are enrolled, and request documentation of all three eligible indications so the broadest clinical justification is on file.
3. Request a 90-day supply instead of 30-day fills where your plan allows; many plans and pharmacy chains offer a per-tablet discount for 90-day fills.
4. Compare compounded dapagliflozin pricing from licensed 503A pharmacies. Confirm the pharmacy holds a valid RI non-resident pharmacy license (or an in-state license) before transferring your prescription.
5. Use the AZ&Me program if you are uninsured and meet the income threshold (at or below 600% federal poverty level).
6. Enroll through a telehealth platform that bundles prescribing with a pharmacy partner. Some platforms negotiate lower 503A compounding fees that are not available to patients who approach compounders directly.

The FDA-approved Farxiga label and full prescribing information are available through the FDA accessdata portal. Rhode Island patients and prescribers should review the most current label before initiating therapy.

In DAPA-HF, 95.4% of patients who received dapagliflozin 10 mg once daily received their assigned study medication at 8 months, reflecting a tolerability profile that supports sustained real-world use. [1]